Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT
American Journal of Hematology · 2023
DOI: 10.1002/ajh.27046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Lisa Pleyer und 24 weiteren Autor:innen. Beteiligte Einrichtung: Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Azacitidine, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The current gold standard of response assessment in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) is morphologic complete remission (CR) and CR with incomplete count recovery (CRi), both of which require an invasive BM evaluation. Outside of clinical trials, BM evaluations are only performed in ~50% of patients during follow‐up, pinpointing a clinical need for response endpoints that do not necessitate BM assessments. We define and validate a new response type termed “peripheral blood complete remission” (PB‐CR) that can be determined from the differential blood count and clinical parameters without necessitating a BM assessment. We compared the predictive value of PB‐CR with morphologic CR/CRi in 1441 non‐selected, consecutive patients diagnosed with MDS ( n = 522; 36.2%), CMML ( n = 132; 9.2%), or AML ( n = 787; 54.6%), included within the Austrian Myeloid Registry (aMYELOIDr; NCT04438889). Time‐to‐event analyses were adjusted for 17 covariates remaining in the final Cox proportional hazards (CPH) model. DeepSurv, a CPH neural network model, and permutation‐based feature importance were used to validate results. 1441 patients were included. Adjusted median overall survival for patients achieving PB‐CR was 22.8 months (95%CI 18.9–26.2) versus 10.4 months (95%CI 9.7–11.2) for those who did not; HR = 0.366 (95%CI 0.303–0.441; p < .0001). Among patients achieving CR, those additionally achieving PB‐CR had a median adjusted OS of 32.6 months (95%CI 26.2–49.2) versus 21.7 months (95%CI 16.9–27.7; HR = 0.400 [95%CI 0.190–0.844; p = .0161]) for those who did not. Our deep neural network analysis‐based findings from a large, prospective cohort study indicate that BM evaluations solely for the purpose of identifying CR/CRi can be omitted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Austrian Group of Medical Tumor Therapy (AGMT) Study Group, Vienna, Austria.
- Salzburg Cancer Research Institute (SCRI) Center for Clinical Cancer and Immunology Trials (CCCIT), Salzburg, Austria.
- Cancer Cluster Salzburg (CCS), Salzburg, Austria.
- 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Oncologic Center, Paracelsus Medical University, Salzburg, Austria.
- Life & Medical Sciences Institute, University of Bonn, Bonn, Germany.
- Assign Data Management and Biostatistics GmbH, Innsbruck, Austria.
ORCID-Profile: Lisa Pleyer, Heinz Sill
Zitieren
APA
Pleyer, L., Vaisband, M., Drost, M., Pfeilstöcker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Pichler, A., Hartmann, B., Petzer, A., Schreder, M., Schmitt, C. A., Vallet, S., Melchardt, T., Zebisch, A., Pichler, P., Zaborsky, N., …, & Greil, R. (2023). Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT. American Journal of Hematology. https://doi.org/10.1002/ajh.27046
Vancouver
Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT. American Journal of Hematology. 2023. doi:10.1002/ajh.27046
BibTeX
@article{Pleyer2023,
author = {Pleyer, Lisa and Vaisband, Marc and Drost, Manuel and Pfeilstöcker, Michael and Stauder, Reinhard and Heibl, Sonja and Sill, Heinz and Girschikofsky, Michael and Stampfl-Mattersberger, Margarete and Pichler, Angelika and Hartmann, Bernd and Petzer, Andreas and Schreder, Martin and Schmitt, Clemens A and Vallet, Sonia and Melchardt, Thomas and Zebisch, Armin and Pichler, Petra and Zaborsky, Nadja and Machherndl-Spandl, Sigrid and Wolf, Dominik and Keil, Felix and Hasenauer, Jan and Larcher-Senn, Julian and Greil, Richard},
title = {Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine—A prospective cohort study by the AGMT},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.27046}
}
EUVIMED